MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03116nam a22003137a 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
OB 2021 0002 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
PILC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240720153244.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220427b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Language of cataloging |
eng |
| Transcribing agency |
FEU-NRMF MEDICAL LIBRARY |
| Description conventions |
rda |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
english |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
OB 2021 0002 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
A Comparative study on the effect of micronized progesterone and oral dydrogesterone in the treatment of threatened abortion in a tertiary medical center from 2015 to 2019 / |
| Statement of responsibility, etc. |
Denise Elaine A. Reyes; Lylah Reyes; Elizabeth Ahyong-Reyes. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
Fairview, Quezon City: |
| Name of publisher, distributor, etc. |
Department of Obstetrics and Gynecology, FEU-NRMF, |
| Date of publication, distribution, etc. |
2021. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
40 pages: |
| Other physical details |
illustrations, tables; |
| Dimensions |
(in folder) + |
| Accompanying material |
with flash drive (soft copy). |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes appendices and bibliographical references. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Abstract: Threatened abortion occurs in 15% of pregnancies. If not prevented this may lead to pregnancy loss in 20% of cases. But with its resolution, it may lead to a better pregnancy outcome. Progesterone plays a key role in the prevention and management of threated abortion. To determine whether vaginal micronized progesterone is comparable with oral dydrogesterone in the treatment of Threatened abortion. This is a retrospective cohort study involving 573 charts of pregnant patients with threatened abortion who were either given oral dydrogesterone or vaginal micronized progesterone as treatment. Both out- and in-patient charts were reviewed and data extracted by the primary investigator. Baseline maternal characteristics gathered were compared between the two arms. The resolution of symptoms, duration of treatment, occurrence of adverse effects and pregnancy outcome were compared and analyzed between the type of progesterone using chi square and t-test. The resolution of signs and/or symptoms for patients with threatened abortion was not significantly different between those given vaginal micronized progesterone versus those who took oral dydrogesterone (p=0.401). The length of treatment ranged from 7 to 14 days to achieve resolution of signs and/or symptoms. A significantly higher proportion of cases in the oral dydrogesterone arm had nausea and somnolence, while increased vaginal discharge was noted in the vaginal progesterone group (p=0.001). The use of vaginal micronized progesterone and oral dydrogesterone achieved resolution of signs and/or symptoms of threatened abortion generally within 7 days but can be extended for 14 days. Systemic adverse effects of nausea and somnolence were more common in oral dydrogesterone. With micronized progesterone, because of its route of administration, vaginal discharge was more often observed. |
| 521 ## - TARGET AUDIENCE NOTE |
|---|
| Target audience note |
Research - Department of Obstetrics & Gynecology |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
threatened abortion |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
dydrogesterone |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
micronized progesterone |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Reyes, Denise Elaine A., MD. |
| Relator term |
principal investigator |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Reyes, Lylah D., MD. |
| Relator term |
co-author |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ahyong-Reyes, Elizabeth, MD. |
| Relator term |
co-author |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Room Use |
